
	Where results make sense

Topic: Blockbuster drug

Related Topics

Epigenesis

Barak

Radio Shack

USMC

Greek religion

Tewa

Full Moon, Dirty Hearts

List of Oregon mountain ranges

British Dragonfly Society

CPC

1984 in film

List of show business families

In the News (Mon 6 Jul 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Quest for blockbuster obesity drug vexes firms
		Taking the drug could carry with it the risk of side effects such as insomnia, rapid heartbeat and elevated blood pressure, according to data from clinical trials sponsored by BASF Pharma, the company's pharmaceuticals arm.
		Before drugs like Xenical and Meridia can reach their potential, companies say, the possibility of a pharmaceutical treatment for obesity would have to be more widely accepted.
		He said drugs on the market are not very effective "weight-reducing agents, and for most people only have small effect." Some anti-obesity treatments have proved not only hard to stick to but potentially dangerous.
	www.personalmd.com /news/n0817095106.shtml (1112 words)

	Blockbuster Drugs Draw in the Crowds (Site not responding. Last check: 2007-10-10)
		The truly successful ones are known as "blockbuster drugs." Like a box office hit, these pharmaceuticals have the potential to resurrect a drug company's sagging bottom line.
		Blockbuster drugs, by definition, are pharmaceuticals that generate $500 million or more in annual sales.
		This was instrumental in drug development because it was the first time drug manufacturers had the physiology and body chemistry down to a point where they could go and search for a certain type of drug that had a certain type of effect.
	www.priority-health.com /employers/newsletters/priority_at_work/archive/fall_03/02.htm (431 words)

	The Waning Of The Blockbuster Drug
		For a look at how the drug industry is changing, compare the latest news on Big Pharma powerhouse Merck and Co. (MRK), with $22.5 billion in sales last year, and tiny biotech Medarex Inc. (MEDX), which racked up revenues of just $11.2 million.
		Drugs that bring in billions of dollars, such as Lipitor for high cholesterol, Nexium for hyperacidity, and Zoloft for depression, turned pharmaceuticals into one of the globe's most profitable industries, enabling drugmakers to spend $32 billion on research and development last year and put 40,000 sales reps on the street.
		Given that 50% of blockbusters are heavily marketed me-too drugs, offering little benefit over others in their class, the industry is sure to take a financial hit.
	www.businessweek.com /magazine/content/04_42/b3904034_mz011.htm (1466 words)

	Blockbuster drugs: Take the hype in small doses
		For drugs that aim for approval in the United States — a market essential to blockbuster status, since U.S. prices are higher than those in other countries — companies need approval from the Food and Drug Administration to test on humans.
		Of course, when a pipeline drug with a lot of buzz fails to pass FDA scrutiny, or is delayed for unforeseen reasons, it can be bitter medicine for stockholders.
		They should be balanced by the threat that existing blockbusters might soon lose their patent protection or be challenged early by generic drug makers.
	www.iht.com /articles/2003/03/01/mdrug_ed3_.php (1518 words)

	Pfizer Cancels Expected Blockbuster Drug - HealthWatch
		Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, said it is too soon to say whether the entire class of drugs known as CETP inhibitors is dangerous or if there was something specific to torcetrapib that caused the deaths.
		He said that Roche Holding AG is developing drugs of the same type, and there's speculation that Merck and Co. is too.
		Nissen said he will still examine the results of the study, and that if the trial showed that the drug actually increased plaque, it would indicate that there is something wrong with the way the class of drugs works.
	www.nbc5.com /health/10457143/detail.html (952 words)

	Novo Nordisk rumoured to have blockbuster drug in development
		The term "blockbuster" is only used by analysts and the pharmaceutical industry for new products which are expected to achieve sales of at least USD 1 billion (approx.
		Novo Nordisk’s drug candidate — codenamed nn2211 — is a treatment for Type 2 diabetes, which used to be called maturity onset diabetes but is now seen at a rapidly increasing rate in younger generations.
		In terms of drug development nn2211 is currently at the end of phase 2 testing.
	www.investindk.com /visNyhed.asp?artikelID=9553 (251 words)

	Blockbuster Pharmaceutical Launches: Establishing Market Leadership
		Blockbuster brands are consistently supported by efficient, streamlined thought leader development programs designed to win the medical community’s acceptance and propel the drug to rapid peak annual sales.
		Blockbuster brand teams tap the medical community early in development and continue to invest in opinion leaders for a number of purposes, including publications planning, speaker opportunities and continuing medical education...
		Early in a drug's lifecycle, project and brand teams' primary objectives are to start outlining the competitive landscape, identify unmet needs and spot potential problem areas that could inhibit a drug's US commercial development in the years ahead.
	www.cuttingedgeinfo.com /pharmaBrandResources/index_blockbusters.htm (643 words)

	Drug development costs hit $1.7 billion (Site not responding. Last check: 2007-10-10)
		When the costs of failed prospective drugs are factored in, the actual cost for discovering, developing and launching a single new drug has risen to nearly $1.7 billion, a 55 per cent increase on the average level between 1995 and 2000.
		Coupled with this is the increasing reluctance of national healthcare systems and insurance companies to foot the bill for new prescription drugs, and an increasingly aggressive generic industry that is lobbying to cut patent protection times.
		Bain believes that the primary reason for the reluctance to shift from this model is that executives are still in a state of denial and reluctant to think beyond the strategies that led to past successes.
	www.drugresearcher.com /news/news-NG.asp?n=48314-drug-development-costs (956 words)

	Boston's The Weekly Dig: News & Opinions: Blockbuster Depression: Drug Deals for Drug Makers (Site not responding. Last check: 2007-10-10)
		In order to reduce prescription drug costs to consumers, at least one proposed bill would limit patents to 30 months on trademarked drugs, at which point generic alternatives would be freely allowed on the market.
		In particular, drugs designed and marketed to modulate brain chemistry — those intended to make a person less depressed, more sociable, happier at work — are currently the hottest segment of pharmaceutical drugs, with over $10.5 billion in sales for the year ending in February 2001.
		With drugs such as Zoloft (under Pfizer’s patent until December of 2005), and other antidepressants already a multi-billion dollar industry aimed at altering mood or “changing” the way a person thinks, feels and acts, the consolidation of drug companies may lead to less diversity of consciousness, more brand-name brain function.
	www.weeklydig.com /articles/blockbuster_depression_drug_deals_for_drug_makers (932 words)

	C&EN: BOOKS - A BLOCKBUSTER DRUG THAT ALMOST WASN'T
		The success of Taxol and to a lesser extent of the camptothecin-derived drugs serves in large measure to justify the program and to argue for its continuance in a time of increasing competition for funds from combinatorial chemistry and other approaches to drug discovery.
		Since ovarian cancer is much less common than breast cancer, BMS estimated the market potential of the drug to be in the range of $200 million to $300 million per year, and there was serious doubt within the company as to the wisdom of bidding on the CRADA.
		It rapidly acquired the status of a "blockbuster" drug, with sales of more than $1 billion per year, in part because of the high drug cost for a course of treatment.
	pubs.acs.org /cen/coverstory/7935/7935books.html (1969 words)

	Drug Delivery Technology - Article Index
		The drug content must be uniformly distributed, confirmed by assay to be consistent with the input composition, and free of contamination.
		Ketoconazole USP is an antifungal drug with an aqueous solubility of 0.017 mg/mL at 25°C. Dissolution of ketoconazole USP powder and commercial ketoconazole tablets reaches approximately 43% and 62% in 30 minutes, respectively (data not shown).
		Finding the right drug delivery technology for poorly water-soluble drugs is a challenge, given the complexity of new drugs in discovery and the growing field of technologies being developed to enhance the performance of poorly soluble drugs.
	www.drugdeliverytech.com /cgi-bin/articles.cgi?idArticle=262 (2760 words)

	Vytorin: Yet Another Cholesterol Drug
		These are meant to sell drugs, not educate consumers, and they only add to the prices you pay.” Even if you follow this wise advice offered by Marcia Angell, MD, in her acclaimed 2004 book, The Truth About Drug Companies, chances are you will have one of the following drugs prescribed by a physician.
		When a blockbuster drug is due to lose its patent protection—and blockbuster is usually defined as sales over a billion dollars a year—the drug company must find creative ways to keep the profits high.
		This drug is the creation of the pharmaceutical giant Merck, which will soon face competition from cost-cutting generic drug companies when its blockbuster cholesterol-lowering drug, Zocor, goes off patent this year.
	www.medicalconsumers.org /pages/VytorinYetAnotherCholesterolDrug.htm (610 words)

	Howrey LLP
		Because these drugs are so critical to the success of their manufacturers, the pharmaceutical industry is in the midst of an unprecedented transformation.
		The effect of a patent on a blockbuster drug can be seen on the bottom lineâ”once a patent expires, it is not unusual for a company to lose 90 percent of its revenue from that drug in the first year.
		These combination drugs may be patentable both as new compositions if unexpected synergies are identified and for new uses that they may have.
	howrey.com /practices/ip/index.cfm?contentID=275 (1397 words)

	KOMO-TV - Seattle, Washington - News Archive - Merck Recalls Blockbuster Arthritis Drug Vioxx
		News of the drug's dangers came from a three-year study aimed at showing that Vioxx could prevent the recurrence of colon and rectal cancer.
		Vioxx and a successor drug called Arcoxia, approved in some other countries and awaiting Food and Drug Administration approval here, are part of a class of anti-inflammatory drugs heavily touted by the pharmaceutical industry as being more effective and having less side effects, particularly on the gastrointestinal system, than older drugs.
		Pfizer's Celebrex and its successor drug, Bextra, which already is on the market in the United States, also are in that class, called cox-2 inhibitors.
	www.komotv.com /news/story.asp?ID=33308 (893 words)

	Blockbuster drug - Wikipedia, the free encyclopedia
		A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year.
		The search for blockbusters has been the foundation of the RandD strategy adopted by big pharmaceutical companies, but this looks set to change.
		A recent report from Urch Publishing estimated that about one third of the pharma market by value is accounted for by blockbusters.
	en.wikipedia.org /wiki/Blockbuster_drug (152 words)

	Essentialdrugs.org (via CobWeb/3.1 planetlab1.cs.wisc.edu) (Site not responding. Last check: 2007-10-10)
		The traditional route to drug discovery, the old pharmacology of testing analogues of active drugs or the slightly newer pharmacology of mass screenings in chemical libraries, is not yet over.
		But neither has rational drug design--the new pharmacology of characterising the receptor and making a drug to fit--come up with a blockbuster, although it may do one day.
		Such rational research has led to licensed drugs, but they are mostly for rare diseases (eg, imatinib for gastrointestinal stromal tumours) or are barely effective, even in combination with traditional therapies (eg, trastuzumab for some advanced breast cancers).
	www.essentialdrugs.org.cob-web.org:8888 /edrug/archive/200410/msg00004.php (504 words)

	Drug firms: no blockbuster results \| The San Diego Union-Tribune (Site not responding. Last check: 2007-10-10)
		NEW YORK – Merck and Co. profits plunged in the third quarter in the wake of the recall of its Vioxx arthritis drug and Eli Lilly and Co. expanded a layoff to 1,000 workers because of falling sales of its anti-psychotic medicine Zyprexa.
		Both show the perils of drug makers relying on a handful of blockbuster medicines.
		"The blockbuster drug model is struggling," said David Moskowitz, an analyst at Friedman Billings, Ramsey in Arlington, Va. "There are fewer and fewer of them around and they are under threat" because generic companies are increasingly challenging patents and insurers are resisting paying for expensive new medicines.
	www.signonsandiego.com /uniontrib/20041022/news_1b22drugs.html (539 words)

	Health Alert 199 - Next Blockbuster Drug for Women Only
		Given the success of Viagra for men, it's no wonder that drug companies are jumping for joy over their latest big rollout—a sex drug for women called Intrinsa.
		For insurance to cover a drug, it must be necessary to treat a disease diagnosis.
		I fear the drug company push to market their new Spanish fly will neglect the need for testing and balancing all sex hormones.
	www.alsearsmd.com /ha199.php (692 words)

	The Hindu Business Line : An Indian twist to Pfizer's blockbuster epilepsy drug
		Pfizer is the patent-holder of this blockbuster drug.
		The judgment was in response to Teva's suit against the introduction of authorised generics of the drug by Pfizer (Pfizer authorises another company to produce a generic version of the same drug).
		The presence of a generic drug authorised by the innovator company also makes the market unattractive for other generic competitors looking to make a killing from making clones of the blockbuster drug.
	www.thehindubusinessline.com /2005/06/09/stories/2005060902880100.htm (623 words)

	Meet the Street: How to Name a Blockbuster Drug
		When we come up with a drug name, we have to be extra careful to make sure that it sounds and looks different enough from another drug.
		The best way to get a drug prescribed is to have a patient go to his doctor and ask for it.
		Years ago, drug brand names were more clinical, but today, drug companies really want names that are sharper and more memorable.
	www.thestreet.com /funds/meetthestreet/10003579.html (628 words)

	Without the Next Blockbuster Drug, Merck Faces a Murky Future - Knowledge@Wharton
		The company faces a dearth of new drugs to replace top sellers due to lost patent protection in the next few years, and it has canceled work on a highly anticipated depression drug that failed in late-stage trials.
		The drug industry, which has enjoyed growth of up to 20% in recent years, was due for a slowdown, Pauly notes.
		Merck’s determination to focus on breakthrough blockbuster drugs, rather than imitate competitors with so-called “me-too” therapies, may be at the root of the company’s current drug drought, says Tong.
	knowledge.wharton.upenn.edu /article.cfm?articleid=886 (1941 words)

	Lilly Cures Inefficiency With IT - News by InformationWeek (Site not responding. Last check: 2007-10-10)
		And the loss of sales to generic drugs is no longer gradual--look at Eli Lilly and Co., which has seen sales of its blockbuster Prozac fall by almost a quarter since its patent expired last year.
		It's so expensive to develop a new drug that companies are mostly looking to develop formulas that will reach blockbuster status, those with at least $400 million in annual sales.
		He estimates 22 drugs approved by the FDA last year became blockbusters, and he predicts the number will remain high, with 18 more this year.
	www.informationweek.com /story/IWK20020215S0001 (797 words)

	The Blockbuster Drug
		It consisted of a number of small drug companies, that were established and operated mostly by refugees from Europe.
		Eli Hurvitz,a former kibbutznik (farmer) assumed its leadership and in the early 1980s set a course for Teva to become a generic drug company, Teva today, is the third largest generic company in the world.
		He gambled heavily on acquiring the know-how, build a $30 million plant, well ahead of being sure that the pharmaceutical trade-named Copaxone, could be produced or would reduce the relapse rate in patients with relapsing-remitting multiple sclerosis and also encourage the release of a factor that helps protect the brain from axonal loss.
	www.ishitech.co.il /0303ar7.htm (382 words)

	Xigris set to be blockbuster - Jan. 9, 2002
		The drug is expected to be a strong revenue-driver for Lilly
		On Nov. 21, the U.S. Food and Drug Administration approved Xigris for the treatment of adult patients with severe sepsis who have an especially high risk of dying from the disease.
		Mark Striker, drug analyst for Salomon Smith Barney, estimated total 2001 sales for the drug of $20 million, and he expects sales to jump to $400 million in 2002.
	money.cnn.com /2002/01/09/companies/lilly_xigris/index.htm (459 words)

	Drug Injury Watch: Propulsid: Blockbuster Drug With Danger Signals That Were Ignored
		Federal officials told Propulsid's manufacturer, Johnson and Johnson, that the drug might have to be banned for children, or even withdrawn altogether.
		In fact the parallels between Propulsid and the painkillers is so striking that the FDA advisory panel which heard evidence in February 2005 about whether Vioxx, Bextra, and Celebrex increased the risk of heart attacks and strokes made reference to Propulsid.
		DRUG INJURY WATCH is for general information purposes only, and should not be regarded as medical advice nor legal advice.
	www.drug-injury.com /druginjurycom/2005/09/propulsid_an_ea.html (1125 words)

	[No title]
		Amidst the billion-dollar competition to create the newest blockbuster drug, there's one thing worth more than all the ads money can buy: a single positive mention in a respected medical journal.
		The drug companies are writing the studies and having medical doctors sign their names on it and then having the study published in a prestigious journal.
		It is an incredibly sweet deal for the drug company, as it is only a small fraction of the over one billion they spent on marketing to consumers last year, yet produces enormous benefits, as the endorsements in the journals frequently convince many physicians to prescribe their products.
	www.mercola.com /2001/jun/6/drug_companies.htm (735 words)

	FOXNews.com - Merck Withdraws Blockbuster Arthritis Drug Vioxx - Business And Money \| Business News \| Financial News
		NEW YORK — Merck and Co. (MRK) Thursday pulled its arthritis drug Vioxx off the market because it increases the risk of heart attack and stroke, a move that sent its shares plunging, erasing $25 billion of its market value.
		Merck said it is withdrawing the drug following data from a new three-year trial of Vioxx, designed to evaluate the effectiveness of the drug's standard 25 milligram dose in preventing recurrence of colorectal polyps.
		Merck had expected Vioxx to help restore the company's earnings growth when the drug was launched in 1999, but its sales have been hurt by clinical trial data showing it increased the incidence of blood clots tied to strokes and heart attacks.
	www.foxnews.com /story/0,2933,134057,00.html (698 words)

Try your search on: Qwika (all wikis)